Literature DB >> 8035913

Enantioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin1 receptor antagonist CP-99,994.

F D Tattersall1, W Rycroft, R G Hill, R J Hargreaves.   

Abstract

These studies have examined the effects of the selective neurokinin1 (NK1) receptor antagonist CP-99,994 on the retching and vomiting response to apomorphine. CP-99,994 (1-3 mg/kg i.p.) attenuated retching and vomiting induced by apomorphine (0.25 mg/kg s.c.) with complete inhibition of retching and vomiting at the 3 mg/kg dose. In contrast CP-100,263 (3 mg/kg i.p.), the enantiomer of CP-99,994 with 1000-fold lower affinity for the NK1 receptor, was without effect.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8035913     DOI: 10.1016/0028-3908(94)90018-3

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  16 in total

1.  The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret.

Authors:  J A Rudd; C C Jordan; R J Naylor
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

2.  The emetic and anti-emetic effects of the capsaicin analogue resiniferatoxin in Suncus murinus, the house musk shrew.

Authors:  P L Andrews; F Okada; A J Woods; H Hagiwara; S Kakaimoto; M Toyoda; N Matsuki
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 3.  New perspectives in antiemetic treatment.

Authors:  J Herrstedt
Journal:  Support Care Cancer       Date:  1996-11       Impact factor: 3.603

4.  The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040.

Authors:  C J Gardner; D J Twissell; T J Dale; J D Gale; C C Jordan; G J Kilpatrick; C Bountra; P Ward
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

Review 5.  Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.

Authors:  Mark G Kris; Paul J Hesketh; Jorn Herrstedt; Cynthia Rittenberg; Lawrence H Einhorn; Steven Grunberg; Jim Koeller; Ian Olver; Sussanne Borjeson; Enzo Ballatori
Journal:  Support Care Cancer       Date:  2004-11-23       Impact factor: 3.603

Review 6.  Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds.

Authors:  C Veyrat-Follet; R Farinotti; J L Palmer
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

7.  Fosaprepitant versus ondansetron for the prevention of postoperative nausea and vomiting in patients who undergo gynecologic abdominal surgery with patient-controlled epidural analgesia: a prospective, randomized, double-blind study.

Authors:  Tomohiro Soga; Katsuyoshi Kume; Nami Kakuta; Eisuke Hamaguchi; Rie Tsutsumi; Ryosuke Kawanishi; Kohei Fukuta; Katsuya Tanaka; Yasuo M Tsutsumi
Journal:  J Anesth       Date:  2015-03-24       Impact factor: 2.078

8.  The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor.

Authors:  J W Watson; S F Gonsalves; A A Fossa; S McLean; T Seeger; S Obach; P L Andrews
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

9.  Oral administration of aprepitant to prevent postoperative nausea in highly susceptible patients after gynecological laparoscopy.

Authors:  Wol Seon Jung; Yong Beom Kim; Hee Yeon Park; Woo Jong Choi; Hong Seuk Yang
Journal:  J Anesth       Date:  2012-12-06       Impact factor: 2.078

10.  The effect of aprepitant for the prevention of postoperative nausea and vomiting in patients undergoing gynecologic surgery with intravenous patient controlled analgesia using fentanyl: aprepitant plus ramosetron vs ramosetron alone.

Authors:  Se-Jin Lee; Su Myung Lee; Soon Im Kim; Si Young Ok; Sang Ho Kim; Sun-Young Park; Mun-Gyu Kim
Journal:  Korean J Anesthesiol       Date:  2012-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.